About Bio-Techne Corp

Bio-Techne Corp, formed through strategic acquisitions and organic growth, has become a leading provider of life science research tools and diagnostic products serving the global research community. The company has built a comprehensive portfolio of brands and products essential for biological research and drug development. TECH stock price reflects the company's market leadership and exposure to life sciences research funding and biopharmaceutical innovation.

Led by CEO Kim Kelderman, Bio-Techne has successfully expanded its product portfolio through strategic acquisitions while maintaining operational excellence and innovation capabilities. The management team has focused on building market-leading positions in attractive life sciences markets. Leadership's strategic vision for providing essential tools across the research workflow has been instrumental in driving consistent growth and supporting TECH stock price appreciation.

Bio-Techne operates by developing, manufacturing, and marketing research reagents, instruments, and diagnostic products used in life sciences research, drug discovery, and clinical diagnostics. The company serves academic institutions, biopharmaceutical companies, and diagnostic laboratories worldwide with products essential for biological research. With continued growth in life sciences research funding, increasing biopharmaceutical R&D investment, and Bio-Techne's established market positions and innovative product pipeline, TECH offers investors exposure to fundamental life sciences research trends with strong competitive moats, recurring revenue characteristics, and potential for continued market expansion through innovation and strategic acquisitions.